Ascendis Pharma A/S (NASDAQ: ASND) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $171.00 price target on the stock, up previously from $146.00.
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United StatesGlobeNewswire
- How Turner and Achondroplasia Data plus Board Addition Could Shape Ascendis Pharma's (ASND) Pipeline Strategy [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial [Yahoo! Finance]Yahoo! Finance
- Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention [Yahoo! Finance]Yahoo! Finance
ASND
Earnings
- 2/11/26 - Miss
ASND
Sec Filings
- 4/1/26 - Form 3
- 3/30/26 - Form 6-K
- 3/24/26 - Form 6-K
- ASND's page on the SEC website